Drug Discovery World

FEBRUARY 22, 2024

With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.

Clinical Trials 130

Clinical Trials Trials Small Molecule Compound Screening 130

Drug Discovery World

APRIL 11, 2024

It was announced that the next AACR Annual Meeting will take place in Chicago on 25-30 April 2025. Treatment of BRCA2-deficient but not wild-type DLD1 cells with BSM-1516 resulted in cell cycle arrest accompanied by DNA damage signalling and accumulation of chromatin-bound RPA32, a marker of ssDNA.

Biochemical Assays 130

Biochemical Assays DNA Science Pharmacokinetics 130

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. How does SRP-001’s safety profile, especially concerning hepatotoxicity and nephrotoxicity, compare to other common pain medications?

Treatment 59

Treatment Clinical Trials Molecular Biology Therapies 59

New Drug Approvals

SEPTEMBER 13, 2024

2] [3] [4] A regulatory application for approval of the medication is expected to be submitted by 2025. [2] 7] Aticaprant was also under development for the treatment of alcoholism , cocaine use disorder , and smoking withdrawal , but development for these indications was discontinued. [2] 2] Aticaprant is taken by mouth. [1]

Treatment 57

Treatment Pharmacokinetics Clinical Trials Pharmaceuticals 57

Drug Discovery World

OCTOBER 25, 2022

This proprietary formulation of psilocin has the potential to deliver a more consistent and controllable response in patients, with a rapid onset, significantly shorter treatment duration and less variability compared to oral formulations of psilocybin. . Discontinuation of evaluating oral psilocybin for the treatment of SUNHA .

Clinical Trials 130

Clinical Trials Pharmacokinetics Science Therapies 130

Alta Sciences

JULY 31, 2024

Food and Drug Administration (FDA) published a draft guidance to ensure greater diversity in clinical trials, which is expected to become a final guidance by June 2025. Furthermore, there are cases in which certain racial groups biologically react to particular conditions or treatments.

Clinical Trials 52

Clinical Trials Trials Clinical Pharmacology Pharmacokinetics 52

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Agency IQ

FEBRUARY 15, 2024

CDRH FY2024 Guidance Agenda Clinical application Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma CBER Final By 12/31/24 CBER CY 2024 Guidance Agenda Blood Considerations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method CBER Draft (..)

FDA 40

FDA Science Biosimilars Production 40

FDA Law Blog: Drug Discovery

JULY 9, 2024

This could be based on differential pharmacokinetics (“PK”) or pharmacodynamics (“PD”), possible differences in susceptibility to specific adverse events of concern, or due to differential presentation of the disease or condition. We hope the answers to these and other questions are coming.

FDA 59

FDA Clinical Trials Disease Trials 59